Trimetazidine in conditions other than coronary disease, old drug, new tricks?

Autor:	Lin-Yan Qian, Hai Zou, Ya-Hui Ding, Qin-Yang Jin, Xing-Xing Zhu, Xue-Jiang Cen, Dong-Sheng Huang
Rok vydání:	2017
Předmět:	0301 basic medicine Drug medicine.medical_specialty Diabetic Cardiomyopathies Vasodilator Agents media_common.quotation_subject Trimetazidine Cardiomyopathy Contrast-induced nephropathy Antineoplastic Agents Coronary Artery Disease 030204 cardiovascular system & hematology Mitochondria Heart Nephropathy Coronary artery disease Sepsis 03 medical and health sciences 0302 clinical medicine Internal medicine Diabetic cardiomyopathy medicine Humans media_common business.industry Drug Repositioning Acetyl-CoA C-Acyltransferase medicine.disease 030104 developmental biology Cardiology Kidney Diseases Cardiology and Cardiovascular Medicine business Chemically-Induced Disorders medicine.drug
Zdroj:	International Journal of Cardiology. 234:1-6
ISSN:	0167-5273
DOI:	10.1016/j.ijcard.2017.02.083
Popis:	Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2d4d03f7f17191f9fa3cfec6a5fb7f https://doi.org/10.1016/j.ijcard.2017.02.083 Zobrazit plný text záznamu Full Text from ScienceDirect